Osvyrti Purple Book BLA 761424

BLA number
761424
Proprietary names
Osvyrti, Jubereq
Proper names
denosumab-desu
Applicant
Accord BioPharma Inc.
Center
CDER
First observed release
2025-11-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Osvyrtidenosumab-desu351(k) Interchangeable60MG/MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2025-10-29
002Jubereqdenosumab-desu351(k) Interchangeable120MG/1.7ML (70MG/ML)InjectionSubcutaneousSingle-Dose VialRxLicensed2025-10-29

Reference Biological Product#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125320Proliadenosumab351(a)Rx2026-06-01

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2025-11-01N001Osvyrti351(k) InterchangeableRxAccord BioPharma Inc.
2025-11-01N002Jubereq351(k) InterchangeableRxAccord BioPharma Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2025-11-01001Osvyrti351(k) InterchangeableRxLicensed2025-10-29
2025-11-01002Jubereq351(k) InterchangeableRxLicensed2025-10-29